Neose Technologies said it will reduce its staff by 35% in connection with the discontinuation of NE-180 (GlycoPEGylated erythropoietin), its experimental erythropoiesis-stimulating agent (ESA) for the treatment of anemia in patients with chronic kidney disease and cancer patients receiving chemotherapy.